Semantic Scholar uses AI to extract papers important to this topic.
Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast… Expand BACKGROUND
Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5 year and 10… Expand Selective estrogen receptor modulators (SERMs) mimic estrogen action in certain tissues while opposing it in others. The… Expand Raloxifene is a selective estrogen receptor modulator that has been shown to prevent bone loss in postmenopausal women. Whether… Expand CONTEXT
Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but… Expand CONTEXT
Raloxifene hydrochloride is a selective estrogen receptor modulator that has antiestrogenic effects on breast and… Expand Oestrogens exert their physiological effects through two receptor subtypes. Here we report the three‐dimensional structure of the… Expand BACKGROUND
Long-term estrogen therapy can reduce the risk of osteoporotic fracture and cardiovascular disease in postmenopausal… Expand The transactivation properties of the two estrogen receptors, ERalpha and ERbeta, were examined with different ligands in the… Expand Medical practice is constantly changing. The rate of change is accelerating, and physicians can be forgiven if they often find it… Expand